Quick Facts

• Approved Area of Use: Management of urolithiasis (kidney and urinary tract stones).
• Associated Benefits: Helps in the passage of existing stones and may support the reduction of muscle spasms associated with renal colic.
• Additional Use: May be indicated for temporary symptom relief associated with mild urinary tract infections.

---

What Rowatinex Treats: Main Uses and Benefits

Rowatinex is a medicinal product with therapeutic indications in the management of urolithiasis, which involves the presence of kidney and urinary tract stones. It is utilized to support the natural process of stone and fragment passage from the urinary system.

The essential oils in this preparation are intended to provide relief from the symptoms often associated with the presence of stones. These benefits include addressing the muscle spasms that contribute to the pain of renal and urinary colic.

Furthermore, the use of this product may be considered for the relief of minor discomforts connected to mild urinary tract infections. All usage and specific treatment protocols should be undertaken following a definitive diagnosis and the advice of a healthcare professional.

The primary goal of treatment is to assist in the elimination of calculi fragments from the system.

Regulatory References

1. HPRA therapeutic overview

This section outlines the official eligibility and exclusion criteria for Rowatinex, strictly based on regulatory documentation.

Contraindicated Populations

Rowatinex is absolutely contraindicated for patients with a known hypersensitivity (allergy) to the active substances (e.g., alpha-pinene, cineole) or to any of the product's excipients.

Age-Related Eligibility

Age Group	Eligibility Status (Regulatory)
Aged 6 years and older	Use is established and allowed.
Aged 0 to 6 years	Not recommended due to no data available on safety and efficacy.

Restricted and Conditional Use

Rowatinex should only be used during pregnancy or lactation if its use is considered essential by the physician, as there is limited information on experience during human pregnancy.

Use requires caution in patients concomitantly taking anti-coagulants (blood thinners) or other medicines that are heavily dependent on the liver for metabolism and excretion.

Additionally, a definite diagnosis of urolithiasis or nephrolithiasis must be made by a doctor before the product is taken.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Rowatinex, strictly based on government regulatory documentation and prescribing information.

Interaction scope

Feature	Details
Medicinal product categories with documented interactions	Anti-coagulants; Medicinal products dependent on the liver for metabolism and excretion
Specific interacting medicines (if explicitly listed)	Warfarin (listed in regulatory patient information as an example of an anti-coagulant)
Mechanistic basis of interactions (only if stated in label)	Potential alteration of metabolism and excretion for liver-dependent medicines (Pharmacokinetic risk); Potential additive effect with anti-coagulants (Pharmacodynamic risk)
Timing-based interaction rules (if applicable)	None officially documented for co-administration with other medicinal products.

---

Interaction classifications (high-level)

Classification	Details
Interaction severity classification (as defined in official documents)	Use with Caution (Caution is mandatory when co-administered with the documented classes.)
Interaction-context constraints (as defined in official documents)	Must be used with caution in patients receiving the listed medicinal products.

---

Resulting interaction structure

Official interaction statements:

• Caution is mandatory when Rowatinex is co-administered with anti-coagulants.
• The regulatory label requires caution for use in patients receiving medicinal products that are dependent on the liver for metabolism and excretion.
• No drug–drug combinations are officially listed as formally contraindicated in the regulatory documents.

The regulatory documents define the product’s interaction structure solely through a cautionary restriction applied to two specific classes of co-administered medicinal products. These official statements establish constraints on co-administration due to potential additive effects or altered metabolism for the co-administered medicine, without specifying mandatory timing rules or outright prohibitions. No interactions with food, alcohol, or herbal products are explicitly documented.

How Rowatinex Works: A Mechanistic Overview

---

Modulation of Renal Smooth Muscle Signaling

This domain centers on the drug's effect on smooth muscle contractility within the urinary tract. Rowatinex engages specific ion channels and receptor-mediated pathways to reduce spasm and normalize muscle tone, resulting in the adjustment of smooth muscle tone and modification of localized pressure within the urinary tract.

---

Regulation of Calciotropic Pathways

Rowatinex influences key pathways associated with the precipitation and dissolution of calcium salts. This involves modifying the activity of cellular enzymes and mediators that regulate the supersaturation of urine, which modifies crystal nucleation and aggregation kinetics by altering local microenvironmental factors, influencing the precipitation tendency of calcium salts.

---

Engagement of Diuretic and Vasodilatory Mechanisms

This cluster addresses the drug's action on renal blood flow and fluid dynamics. Rowatinex promotes localized vasodilation in the kidney, which in turn enhances urine output (diuresis) and renal perfusion, thereby enhancing the washout potential and volumetric clearance within the renal collecting system.

---

Influence on Anti-Inflammatory Signaling Cascades

The drug initiates or suppresses signaling sequences related to tissue inflammation and pain transmission in the urogenital system. By modulating the release and activity of key inflammatory mediators, Rowatinex attenuates the localized pro-inflammatory cascade, leading to predictable downstream physiological adjustments.

Administration Guidelines

Rowatinex is administered via the oral route as a gastro-resistant soft capsule. Standard usage instructions define the dosing frequency, the timing relative to food intake, and the proper handling of the capsule to ensure the medicine is used as intended.

---

Labeled Dosing and Frequency

Population	Dose per Administration	Frequency
Adults and Adolescents (over 14 years)	1 capsule	4 to 5 times daily
Children (6 to 14 years)	1 to 2 capsules	Twice daily

---

Procedural Administration Instructions

This medicine must be taken before meals. The gastro-resistant capsule must be swallowed whole with water and must not be bitten or chewed. This constraint ensures the active terpene combination bypasses the stomach acid, allowing for optimal absorption as outlined in the formulation design.

Patients using the product are instructed to increase their liquid intake during the course of administration. If a dose is forgotten, a double dose should not be taken to compensate; instead, the next dose should be taken at the next scheduled time. No data are available for use in children under 6 years of age.

Rowatinex: Recent Clinical Evidence

---

Evidence for Use in Stone Fragment Clearance After ESWL

The terpene combination was studied in research exploring support for stone fragments left behind following a procedure called Extracorporeal Shock Wave Lithotripsy (ESWL). The research design primarily included Randomized Controlled Trials (RCTs), where adult patients undergoing ESWL were compared to groups receiving a placebo or other active treatments. These studies monitored the total clearance of stone fragments, known as the Stone-Free Rate (SFR), and tracked the time required for clearance to occur over a period of weeks. Studies monitored measurements of fragment clearance over periods typically extending up to 12 weeks post-ESWL. The long-term effects on the recurrence of stones are not well characterized.

Evidence for Use in Spontaneous Ureteral Stone Passage

The terpene combination was evaluated in trials focused on observing spontaneous passage of ureteral stones (stones in the tube connecting the kidney to the bladder). These studies typically involved short-term RCTs that explored outcomes related to physical discomfort in a research setting. Researchers examined the Stone Expulsion Rate (SER) and the time it took for the stone to pass completely. Research also monitored patient experiences by tracking the number of painful episodes (renal colic) and the use of pain relief medication.

Evidence in Special Populations and Research Limitations

The majority of high-quality research and RCTs was conducted exclusively on the adult population. Few data are available for children, with the existing information consisting mainly of small case series. Dedicated, large-scale controlled studies to understand the outcomes in the pediatric population remain unavailable. Data for certain groups, such as those with specific comorbidities or those requiring use during pregnancy, remain insufficient.

Comparative evidence for both spontaneous passage and fragment clearance against newer pharmacological agents is limited, and long-term effects are not fully established.

Key Studies & References

1. Rowatinex Gastro-resistant Capsules, Soft - Summary of Product Characteristics (HPRA)
2. The value of Rowatinex in the treatment of ureterolithiasis (Mukamel et al., 1987)
3. Comparison between Rowatinex and Tamsulosin as a Medical Expulsion Therapy for Ureteral Stone (Ahmed et al., 2013)
4. Taming the stone: systematic review on the clinical use of herbal extracts for urolithiasis (Apostolopoulou et al., 2012)

Common questions about Rowatinex (FAQ)

Q: Is Rowatinex available without a prescription in some countries?

Official classification varies by location and regulatory body. Authorities in certain jurisdictions classify the product as a prescription drug (Rx) and require official registration. Therefore, its availability over the counter depends on the specific country or region where it is dispensed.

Q: Are there any known side effects that affect driving or operating machinery?

Regulatory documents state that Rowatinex is unlikely to have any effect on the ability to drive or use machinery. Official product information includes no evidence of impairment of these functions.

Q: Is Rowatinex approved by the FDA?

The drug's regulatory status depends on the country. According to the official Food and Drug Administration (FDA) in certain international jurisdictions, the product is officially registered and classified as a prescription-only medicine. This confirms its status in those regions.

Q: What are the common side effects related to skin reactions?

Official product information describes adverse reactions that may include allergic reactions (hypersensitivity) to the ingredients. Regulatory documents note that these allergic responses can sometimes be possibly delayed following use.

Q: What happens if someone accidentally takes too much Rowatinex?

Official guidance concerning accidental overdose is primarily centered on possible stomach upset (gastric irritation). Regulatory texts indicate that this is the effect that may occur if an excess number of capsules are taken.

How to Store and Dispose of Rowatinex?

The storage and disposal of Rowatinex must strictly follow the official instructions provided in the regulatory labeling to maintain the product's integrity and ensure environmental safety.

Storage Conditions

Requirement	Official Instruction
Temperature Limit	Do not store above 25°C (controlled room temperature).
Packaging	Keep the container tightly closed to protect the soft capsules.
Stability	Do not use this medicine after the expiry date shown on the label/carton.
Safety Rule	Keep this medicine out of the sight and reach of children.

Disposal Instructions

The disposal of unused or expired Rowatinex must adhere to pharmaceutical waste protocols. It is mandatory not to dispose of this medicine via wastewater or household waste. The official procedure requires patients to ask a pharmacist how to properly discard the medicine to ensure the process helps protect the environment.